Caroline A. MacCallum

Caroline A. MacCallum
University of British Columbia - Vancouver | UBC · Department of Medicine

Doctor of Medicine

About

25
Publications
23,169
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
498
Citations
Citations since 2017
24 Research Items
497 Citations
2017201820192020202120222023050100150
2017201820192020202120222023050100150
2017201820192020202120222023050100150
2017201820192020202120222023050100150
Introduction
Dr. Caroline MacCallum is a specialist in internal medicine, with expertise in complex pain and cannabinoid medicine. Her research interests include: cannabis and psychedelics as adjuvants to standard of care and for deprescribing/drug substitution; pharmacovigilance and impairment; and symptomatic and functional improvement in complex conditions with particular focus on fibromyalgia, chronic fatigue, PTSD, TBI and chronic pain.
Additional affiliations
April 2018 - present
University of British Columbia - Vancouver
Position
  • Professor (Associate)
September 2016 - present
University of British Columbia - Vancouver
Position
  • Instructor
January 2016 - present
Greenleaf Medical Clinic
Position
  • Managing Director
Description
  • Duties include physician training, eduction, creating cannabis protocols, group medical visits (biopsychosocial approach to pain), comprehensive consultations, patient advocacy
Education
September 2005 - May 2009
September 2000 - May 2005

Publications

Publications (25)
Poster
Full-text available
Poster based on the publication "A Clinical Framework for Evaluating Cannabis Product Quality and Safety". See here for full manuscript: https://www.liebertpub.com/doi/10.1089/can.2021.0137
Poster
Full-text available
Poster based on the publication “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. See here for full publication: https://www.ejinme.com/article/S0953-6205(21)00152-7/fulltext
Poster
Full-text available
Based on the 2021 publication "Duration of Neurocognitive Impairment With Medical Cannabis Use: A Scoping Review". For full publication, visit: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.638962/full
Article
Increase in medical cannabis use, along with available products, warrants the need for clinicians to be knowledgeable in evaluating the quality of any cannabis product presented in clinical practice. Determining whether a product is regulated within the region is key in assessing overall quality and safety. Regulated products are held to a higher s...
Poster
Full-text available
Poster presentation by Dr. Lauren Eadie and Carly Pistawka at PAINweek 2021 covering medical cannabis as an adjunctive treatment to mitigate adverse events in patients using high-dose opioids for chronic non-cancer pain.
Chapter
Variations in cannabis formulations and methods of administration influence dosing, titration, and monitoring methodology. Smoking/vaporization, oral, oromucosal, and topical routes of administration each have unique pharmacological properties, such as onset and duration of action, that impact the effects experienced.
Chapter
It is imperative both healthcare providers and patients are educated on all aspects of cannabis treatment, including product safety and quality control. There are a number of quality control variables to consider when choosing medical cannabis products including contaminants, microorganisms, and pesticides. Quality control standards reduce or elimi...
Chapter
Recreational cannabis use has been associated with the development of psychosis; as such, there are numerous biopsychosocial risks and vulnerabilities to consider. The Diagnostic and Statistical Manual 5th Edition (DSM-5) has set out a specific set of criteria for cannabis-induced psychotic disorder and other cannabis-induced psychiatric conditions...
Chapter
Opioid overdose (illicit, prescription, nonmedical prescription) is the leading cause of accidental death in the United States. Alternative analgesics are warranted among chronic pain patients given the associated comorbidity and morality related to the long-term use of opioids. Public and professional interest has increased regarding how cannabis...
Chapter
Adolescence is a period for cortical maturation and neuronal development, particularly among frontal areas pertaining to executive function, decision-making, and reasoning. For these reasons, the adolescent brain may be vulnerable to certain substances that can cross the blood-brain barrier such as cannabis. The recreational use of cannabis in adol...
Chapter
In addition to therapeutic benefits, cannabis also causes cognitive and psychomotor impairment in some individuals. Common acute adverse events can be cannabinoid-specific, such as those related to THC (e.g., dizziness, cognitive effects, anxiety, dry mouth) or specific to the route of administration (e.g., cough, phlegm, or bronchitis from smoking...
Chapter
In this chapter, we have summarized systematic reviews of randomized controlled trials using cannabis-based medicine for pain, including, but not limited to, chronic pain (non-cancer pain, neuropathic pain, centralized pain disorders such as fibromyalgia, rheumatic inflammatory pain, cancer pain) and acute pain. It appears that more consistent meth...
Chapter
Cannabis education is an important step toward mitigating risks and promoting patient safety. It is important for healthcare providers to understand the considerations, precautions, relative contraindications, and contraindications associated with cannabinoid use. This allows for healthcare providers to accurately assess the benefits and risks of m...
Chapter
Adolescents and adults increasingly view cannabis as harmless. While the majority can use cannabis without harm, there are many potential problems including decline in educational or occupational functioning after early adolescent use, impaired driving, cannabis use disorders, cannabis withdrawal, and psychiatric comorbidity.
Article
Full-text available
Background Globally, medical cannabis legalization has increased in recent years and medical cannabis is commonly used to treat chronic pain. However, there are few randomized control trials studying medical cannabis indicating expert guidance on how to dose and administer medical cannabis safely and effectively is needed. Methods Using a multista...
Article
Full-text available
Medical cannabis use is increasing worldwide. Clinicians are commonly asked by patients to provide guidance on its safety and efficacy. Although there has been an increase in research on the role of medical cannabis for a number of different conditions, we found that there was a paucity of clear safety guidance on its use. We aim to address this is...
Article
Full-text available
Background: Chronic non-cancer pain (CNCP) is estimated to affect 20% of the adult population. Current United States and Canadian Chronic non-cancer pain guidelines recommend careful reassessment of the risk-benefit ratio for doses greater than 90 mg morphine equivalent dose (MED), due to low evidence for improved pain efficacy at higher morphine e...
Article
Full-text available
While the recreational use of cannabis has well-established dose-dependent effects on neurocognitive and psychomotor functioning, there is little consensus on the degree and duration of impairment typically seen with medical marijuana use. Compared to recreational cannabis users, medical cannabis patients have distinct characteristics that may modi...
Article
Full-text available
Introduction Chronic pain and co-occurring disorders, such as sleep disorders, anxiety, depression, post-traumatic stress disorder and substance use disorders, are among the most common conditions for which cannabis and cannabinoid-based products derived from the cannabis plant (CBP) are used for therapeutic purposes. However, healthcare providers...
Article
Full-text available
Background: Cannabis is commonly used for its medical properties. In particular, cannabis is purported to have beneficial effects on a wide range of neuropsychiatric conditions. Studies assessing mental health in cannabis dispensary users typically evaluate symptoms using self-report check lists, which provide limited information about symptom sev...
Article
Full-text available
Cannabis has been employed medicinally throughout history, but its recent legal prohibition, biochemical complexity and variability, quality control issues, previous dearth of appropriately powered randomised controlled trials, and lack of pertinent education have conspired to leave clinicians in the dark as to how to advise patients pursuing such...
Poster
Full-text available
Inflammatory bowel diseases (IBD) including Crohn’s disease and ulcerative colitis are incurable diseases of the gastrointestinal tract characterized by severe abdominal cramps, chronic diarrhea, weight loss, rectal bleeding, and pain. IBD is most often diagnosed in adolescence and young adulthood, with a rising incidence and prevalence in pediatri...

Network

Cited By

Projects